Glutamatergic medications for the treatment of drug and behavioral addictions

Michael Olive, Richard M. Cleva, Peter W. Kalivas, Robert J. Malcolm

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is a relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.

Original languageEnglish (US)
Pages (from-to)801-810
Number of pages10
JournalPharmacology Biochemistry and Behavior
Volume100
Issue number4
DOIs
StatePublished - Feb 2012

Fingerprint

Substance-Related Disorders
Molecular Mechanisms of Pharmacological Action
Cycloserine
Memantine
Gambling
Acetylcysteine
Nicotine
Synaptic Transmission
Pharmaceutical Preparations
Opioid Analgesics
Neurotransmitter Agents
Substitution reactions
Pharmacology
Ligands
Therapeutics
modafinil
gabapentin
acamprosate
topiramate
lamotrigine

Keywords

  • Behavioral addiction
  • Drug addiction
  • Glutamate
  • Pathological gambling
  • Pharmacological therapy
  • Substance abuse

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Pharmacology
  • Toxicology
  • Behavioral Neuroscience
  • Biological Psychiatry

Cite this

Glutamatergic medications for the treatment of drug and behavioral addictions. / Olive, Michael; Cleva, Richard M.; Kalivas, Peter W.; Malcolm, Robert J.

In: Pharmacology Biochemistry and Behavior, Vol. 100, No. 4, 02.2012, p. 801-810.

Research output: Contribution to journalArticle

Olive, Michael ; Cleva, Richard M. ; Kalivas, Peter W. ; Malcolm, Robert J. / Glutamatergic medications for the treatment of drug and behavioral addictions. In: Pharmacology Biochemistry and Behavior. 2012 ; Vol. 100, No. 4. pp. 801-810.
@article{89977a4c88b34d2ebf2afb54d5f4c98a,
title = "Glutamatergic medications for the treatment of drug and behavioral addictions",
abstract = "Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is a relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.",
keywords = "Behavioral addiction, Drug addiction, Glutamate, Pathological gambling, Pharmacological therapy, Substance abuse",
author = "Michael Olive and Cleva, {Richard M.} and Kalivas, {Peter W.} and Malcolm, {Robert J.}",
year = "2012",
month = "2",
doi = "10.1016/j.pbb.2011.04.015",
language = "English (US)",
volume = "100",
pages = "801--810",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Glutamatergic medications for the treatment of drug and behavioral addictions

AU - Olive, Michael

AU - Cleva, Richard M.

AU - Kalivas, Peter W.

AU - Malcolm, Robert J.

PY - 2012/2

Y1 - 2012/2

N2 - Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is a relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.

AB - Historically, most pharmacological approaches to the treatment of addictive disorders have utilized either substitution-based methods (i.e., nicotine replacement or opioid maintenance) or have targeted monoaminergic or endogenous opioidergic neurotransmitter systems. However, substantial evidence has accumulated indicating that ligands acting on glutamatergic transmission are also of potential utility in the treatment of drug addiction, as well as various behavioral addictions such as pathological gambling. The purpose of this review is to summarize the pharmacological mechanisms of action and general clinical efficacy of glutamatergic medications that are currently approved or are being investigated for approval for the treatment of addictive disorders. Medications with effects on glutamatergic transmission that will be discussed include acamprosate, N-acetylcysteine, d-cycloserine, gabapentin, lamotrigine, memantine, modafinil, and topiramate. We conclude that manipulation of glutamatergic neurotransmission is a relatively young but promising avenue for the development of improved therapeutic agents for the treatment of drug and behavioral addictions.

KW - Behavioral addiction

KW - Drug addiction

KW - Glutamate

KW - Pathological gambling

KW - Pharmacological therapy

KW - Substance abuse

UR - http://www.scopus.com/inward/record.url?scp=84855534956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855534956&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2011.04.015

DO - 10.1016/j.pbb.2011.04.015

M3 - Article

C2 - 21536062

AN - SCOPUS:84855534956

VL - 100

SP - 801

EP - 810

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 4

ER -